Moving forward in the direction guided by Jingqi - a record of the extraordinary development of Yangzijiang Pharmaceutical Group in ten years

Author: China Medical News Feng Yuhao

"The report of the 20th National Congress of the Communist Party of China put forward important expressions such as 'high-quality development is the primary task of building a modern socialist country in an all-round way' and 'accelerating the implementation of innovation-driven development strategy', and we are encouraged
as pharmaceutical people 。 Xu Haoyu, secretary of the party committee, chairman and general manager of Yangzijiang Pharmaceutical Group (hereinafter referred to as Yangzijiang Pharmaceutical), said that the requirements of policies and the needs of the people are the direction of the enterprise, and the group will strive to integrate its own development into the development of the party and the country, adhere to quality advantages, achieve high-quality development of the group with innovation and breakthroughs, and show greater responsibility and greater achievements
in promoting the construction of a healthy China.

Since the 18th National Congress of the Communist Party of China, China's pharmaceutical industry has developed
rapidly.
In the magnificent new era, Yangzijiang Pharmaceutical has achieved quantitative growth and quality improvement in business indicators and product pipelines, and answered the industry questions
of "for whom to make pharmaceuticals" and "why to develop" with practical actions.
With the victory of the 20th National Congress of the Communist Party of China, Yangzijiang Pharmaceutical will continue to explore the upstream and downstream of the health industry, and give the "Yangtze River answer" of "what kind of problem to solve"
with practical actions.

For whom is it pharmaceutical?

"High shore for valley, deep valley for mausoleum" is a true portrayal of
the changes in the pharmaceutical industry in the new era in the past 10 years.
In the great changes of the times, Yangzijiang Pharmaceutical's pursuit of quality has never changed
.
The must-answer question of "for whom to make medicine" has been repeatedly answered by the quality culture of Yangzijiang Pharmaceutical's "pharmacy for relatives and parents", and the word "quality" has penetrated into the bone marrow
of Yangzijiang people.
With the concept of 'big quality' with drug quality as the core and taking into account product quality, service quality and development quality, Yangzijiang Pharmaceutical has burst into great vitality
in the reform of the drug review and approval system (hereinafter referred to as the drug review reform).

The core of drug review reform is to improve the quality of drugs, and generic drugs are the main body used by patients, and their efficacy and quality have a profound impact on public health
.
As the focus of drug review reform, the consistency evaluation of generic drugs has caused shocks in the industry as soon as it was
launched.
This is an inflection point in the pharmaceutical industry, some pharmaceutical companies have to leave the past policy hotbed with difficulty, while the industry leaders represented by Yangzijiang Pharmaceutical have ushered in the opportunity
for rapid growth again in the changes.

With decades of hard work in adhering to the quality of drugs, Yangzijiang Pharmaceutical quickly adapted to the new policy environment and continues to lead the entire pharmaceutical industry
.
At present, the Group has a total of 124 varieties that have passed or deemed to have passed the consistency of generic drugs, of which 31 are the first in China, ranking first
among pharmaceutical enterprises in China in terms of the total number of evaluations.
Yangzijiang Pharmaceutical has a total of 43 varieties selected for national centralized procurement, including docetaxel injection, metformin vildagliptin tablets, etc.
, so that patients can receive the same quality of treatment effect
as the original drug at an affordable price.

In addition to the field of chemical medicine, Yangzijiang Pharmaceutical has also maintained a consistent pursuit of excellence in the field of traditional Chinese medicine, sparing no effort
in improving the quality of drugs.

In order to control the quality of Chinese medicine products from the source, up to now, the Group has established bases for Chinese medicinal materials in 15 provinces across the country, starting from site selection, seedling breeding and field management, and carrying out strict standardized control
on harvesting, production, inspection, storage, transportation and circulation.
In order to reduce the interference of human factors and further control product quality, Yangzijiang Pharmaceutical has also taken the lead in exploring intelligent production plants
for traditional Chinese medicine in the industry.
The Longfengtang factory, which the Group invested more than 3 billion yuan, has set a benchmark
for the integration of domestic traditional Chinese medicine production and modern information technology.
Taking the factory's "Alpha Test 1 Intelligent Inspection Robot for Traditional Chinese Medicine" project as an example, the project is the first in China, which can be applied to the pre-treatment and extraction link of the constant analysis of traditional Chinese medicine inspection, which solves the problems of error, inaccurate data and repeated detection of Chinese medicinal materials due to manual testing in the pre-treatment process, and ensures the uniformity and stability
of product quality.

The picture shows the all-round intelligent testing robot Alpha Test 1

"1% failure can lead to 100% failure
.
" This is management guru Philip Crosby's brilliant interpretation of the butterfly effect in the field of quality management, where even the slightest deviation in execution can lead to the worst results
.
This also answers the industry's long-standing puzzle, "Why does Yangzijiang Pharmaceutical never tirelessly, day after day, year after year, repeatedly emphasize 'quality'?"

It is this tireless pursuit of quality that has allowed Yangzijiang Pharmaceutical to not only gain the recognition of patients, but also international applause
.
In October this year, Yangzijiang Pharmaceutical and Huawei jointly stood at the award ceremony of the European Foundation for Quality Management (EFQM) in Lyon, France, in which Yangzijiang Pharmaceutical won the EFQM Global Award (formerly the European Quality Award), becoming the first pharmaceutical company
in the world to win the award since the implementation of the new EFQM model in 2019.

On what basis did it develop?

Economist Zhou Qiren once used "big fish and big waves" to describe China's economy, huge enterprises not only enjoy the nourishment of the huge market, but also have to face the high and high market competition, he believes that capable national enterprises, not only to make the scale bigger, the cost to be excellent, but also in the "uniqueness" to break through
.

Yangzijiang Pharmaceutical should not only be a high-quality and low-cost generic drug manufacturer, but also face the future, echo the development line of "innovation" in the new era, and continue to charge to the unsolved disease highland through technological research and development
.

Since its inception, innovation has been written into
the DNA of Yangzijiang Pharmaceutical.
Following the launch of exclusive varieties of gastric soda granules and cubeb gastric pain granules, Yangzijiang Pharmaceutical continues to explore the application of
traditional Chinese medicine in gastric diseases, especially non-erosive gastroesophageal reflux disease.
On April 29 this year, the Center for Drug Review of the State Food and Drug Administration publicly solicited opinions on the guiding principles for the evaluation of the clinical efficacy of new traditional Chinese medicines for chronic gastritis and gastroesophageal reflux disease, guiding pharmaceutical companies to highlight the advantages and characteristics
of traditional Chinese medicine treatment in the research and development of new traditional Chinese medicines for chronic gastritis and gastroesophageal reflux disease.
Yangzijiang Pharmaceutical responded quickly, and more than 3 months later, it reached a cooperation with Xiyuan Hospital of the Chinese Academy of Chinese Medical Sciences on the "Spleen Qinghua Formula" to promote the clinical application
of the formula in a wider range.

The picture shows the marketing press conference of Yangtze River Pharmaceutical's class 1 new drug levonidazole phosphate disodium for injection

In addition to inheriting and innovating traditional Chinese medicines, Yangzijiang Pharmaceutical has also ushered in a harvest moment
in chemical drug innovation.
In 2021, the first chemical class 1 new drug disodium levonidazole phosphate for injection independently developed by Yangzijiang Pharmaceutical was approved for marketing, which is different from the frequency of use twice a day for products with the same indication, the efficacy of levonidazole phosphate disodium for injection can be maintained for 24 hours, which greatly improves patients' medication compliance
.
In addition, its unique molecular structure makes the product without adding solubilizers, reducing the risk of adverse reactions caused by organic solvents, and showing better results in terms of safety
.

Entering the field of biological drugs is another major layout
for Yangtze River Pharmaceutical to implement the innovation-driven strategy.
In the "14th Five-Year Plan", the Group seized market demand, locked in the innovative research and development of macromolecular biodrugs, quickly built a number of innovation platforms such as full-process preclinical biological drug research and development, and invested 5 billion yuan to build Shengsen biopharmaceutical projects to accelerate the creation of a new highland
of modern biopharmaceutical industry.

In the past ten years of the new era, from imitation to creation, "three drugs at the same time", from quantitative change to qualitative change
.
Yangzijiang Pharmaceutical has achieved remarkable results
in the field of innovation.
Up to now, Yangzijiang Pharmaceutical has a total of 4 national R&D platforms and more than
30 innovative drugs under development.
Among them, in terms of biological drugs, the relevant R&D work of Shengsen Biotechnology, a wholly-owned subsidiary of Yangtze River Pharmaceutical, is steadily advancing, and the cooperation with Binhui Biotechnology and Rico Biotechnology in the fields of anti-tumor and vaccine development is also continuing, through the "two-wheel model" of internal innovation and cooperative innovation, Yangzijiang Pharmaceutical continues to explore new models of biomedical development and build a highland
of biomedical industry.

What kind of puzzle to solve?

How far a business can go depends not only on the strategic thinking and ability of the enterprise, but also on the feelings of the entrepreneur
.
How to solve the challenges of "pre-disease", "pre-disease" and "latent disease" in the future aging society, so that public health can benefit on a larger scale? This is a question that Yangzijiang Pharmaceutical has been answering and thinking about for more than 50 years, and it is also a must-answer question
for the pharmaceutical industry in the new era.

In addition to drug treatment, if public health wants to achieve a longer cycle and a wider range of benefits, it is necessary to move the health threshold forward, put health management in daily life, and let the correct concept of health care, effective health food, and accurate health examination enter the lives
of ordinary people.
Since the 18th National Congress of the Communist Party of China, China's health care has made great progress, in addition to continuing to solve the difficulty and high cost of medical treatment, the focus of health work is also changing
from "treatment as the center" to "people's health as the center".
In this context, Xu Haoyu said that the pharmaceutical industry is the main business of the group to firmly become stronger, in addition, the company will also enter the big health industry from a high starting point and in an all-round way, and promote the integrated development
of the five formats of "medicine, medicine, health care, food and tourism".

At present, Jiangsu Huyou Health Technology Co.
, Ltd.
, a subsidiary of Yangzijiang Pharmaceutical, is increasing the development of medicinal and food homologous health care products, and has successively launched more than 20 health care varieties such as yam Guguoduo and red deer bone ammonia; Based on the field of probiotics, Jiangsu Hengkang Biotechnology Co.
, Ltd.
introduces original strains and advanced production technology, and exclusively develops ZW probiotics and their derivative products, which can escort consumers' intestinal health; At the same time, functional medicine, health examination, dental outpatient and other businesses have also landed in Taizhou to provide the public with richer health services
.
In addition, Yangzijiang Pharmaceutical also relies on brand advantages, around the development model of "industry + tourism + culture", actively build a competitive health and medical tourism destination, has built a number of unique cultural attractions including "Longfengtang Traditional Chinese Medicine Exhibition Hall" and "Huaxia Xinglin Shengzhe Hall", while meeting the growing demand of the public for health culture, providing the public with correct health concepts and health care methods
.

The picture shows the big health products displayed by Yangzijiang Pharmaceutical Group at the Boao Forum for Chinese Entrepreneurs

"The group is carrying out a series of activities to study and implement the report of the 20th National Congress of the Communist Party of China, and formulate the next stage of strategic planning
based on the report.
" Xu Haoyu said that under the guidance of the spirit of the 20th National Congress of the Communist Party of China and the "Healthy China" strategy, Yangzijiang Pharmaceutical will continue to accelerate the transformation of R&D, comprehensively deepen the strategy of "three drugs at the same time" of traditional Chinese medicine, chemical medicine and biological medicine, solidly promote the integrated development of "medicine, medicine, health care, food and tourism", continuously meet the growing health needs of the public, and contribute wisdom and strength to the country's strength
and national rejuvenation.